| Abstrakt: |
A study conducted by researchers from the Gause Institute of New Antibiotics in Moscow, Russia, explores the emergence of resistance in Klebsiella pneumoniae, a type of bacteria that is resistant to beta-lactam/beta-lactamase inhibitor combinations. The study used a hollow-fiber dynamic model to simulate treatments with doripenem and doripenem/relebactam combination against carbapenemase-producing K. pneumoniae. The results showed that combined simulations reduced the number of resistant subpopulations, and a pharmacokinetic-based approach was found to be more effective in estimating carbapenem MICs and predicting the emergence of resistance. The study highlights the potential of combining relebactam with doripenem to constrain resistance and the importance of a pharmacokinetic-based approach in predicting resistance occurrence. [Extracted from the article] |
